Last updated: February 7, 2026
What is the nature of the case?
Veloxis Pharmaceuticals, Inc. filed patent infringement litigation against Accord Healthcare, Inc. in the United States District Court for the District of Delaware. The case नंबर 1:22-cv-00909 addresses allegations that Accord Healthcare's generic versions of Veloxis’s drug infringe upon patents held by Veloxis.
When was the case initiated?
The complaint was filed on August 12, 2022. The litigation follows prior patent protections for Veloxis's branded drug, which is typically for formulations or methods related to their immunosuppressive drug, indicated for transplant patients.
What patents are involved?
The patent at issue is U.S. Patent No. 9,082,767, entitled "Extended Release Formulation of Tacrolimus," granted July 22, 2015. The patent claims include methods of administering tacrolimus with specific release profiles and formulations.
What are the allegations?
Veloxis alleges that Accord Healthcare's proposed generic tacrolimus infringes at least claims 1-20 of the '767 patent. The complaint asserts that the defendant's generic product violates patent rights through manufacturing, use, and sale of infringing formulations.
What is the procedural posture?
The case is in early stages; the complaint was filed in August 2022. No dispositive motions or settlement updates have been reported. The case includes typical patent infringement allegations requesting injunctive relief, damages, and attorneys' fees.
What are key legal and strategic implications?
-
Patent validity and enforceability: Veloxis aims to defend its patent rights against accusations of invalidity or unenforceability, which are common defenses in Hatch-Waxman litigations.
-
Filing timing and stay considerations: The case may involve a paragraph IV certification, common in ANDA (Abbreviated New Drug Application) litigation, which can trigger a 30-month stay of FDA approval of the generic.
-
Potential settlement or license discussions: Early-stage patent litigations often resolve through settlement or licensing arrangements before trial.
What are industry and market implications?
Veloxis's patent protection plays a critical role in maintaining exclusivity and market share for its tacrolimus product. The outcome influences market dynamics for generic tacrolimus, widely used in transplant medicine.
What legal precedents or citation points are relevant?
- Hatch-Waxman Act provisions govern this type of litigation, notably paragraph IV certifications.
- Patent validity defenses and infringement defenses are critical components.
- Courts often evaluate patent scope in light of prior art and patent specifications.
Key Takeaways
Veloxis’s patent rights are under active challenge through generic entry filings. The case's resolution depends on patent validity, infringement specifics, and procedural factors. The litigation's outcome could significantly influence the market exclusivity for Veloxis’s tacrolimus formulation.
FAQs
1. What is the significance of a paragraph IV certification?
It signals that a generic applicant believes its product does not infringe any valid patents or that the patents are invalid, often leading to patent infringement lawsuits like this one.
2. How long do patent infringement cases typically last?
They can last from 12 to 36 months, depending on motions, discovery, and settlement timelines.
3. Can Veloxis delay generic approval through litigation?
Yes. Filing a lawsuit within 45 days of notice can trigger a 30-month stay under Hatch-Waxman, delaying FDA approval of the generic.
4. What defenses might Accord Healthcare raise?
Invalidity due to prior art, non-infringement, or unenforceability of the patent based on procedural or substantive grounds.
5. How does this case impact market competition?
A favorable outcome for Veloxis sustains exclusivity, while a ruling on invalidity could open the market for generic competitors, lowering drug prices.
References
- Complaint filed in Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc., D. Del., Aug. 12, 2022.
- U.S. Patent No. 9,082,767.
- Hatch-Waxman Act, 21 U.S.C. § 355(j).
